[Federal Register Volume 78, Number 17 (Friday, January 25, 2013)] [Notices] [Page 5499] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2013-01556] ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; Cerilliant Corporation Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on October 4, 2012, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: ------------------------------------------------------------------------ Drug Schedule ------------------------------------------------------------------------ JWH-250 (6250)............................. I SR-18 also known as RCS-8 (7008)........... I JWH-019 (7019)............................. I JWH-081 (7081)............................. I SR-19 also known as RCS-4 (7104)........... I JWH-122 (7122)............................. I AM-2201 (7201)............................. I JWH-203 (7203)............................. I 2C-T-2 (7385).............................. I JWH-398 (7398)............................. I N-Ethyl-1-phenylcyclohexylamine (7455)..... I 2C-D (7508)................................ I 2C-E (7509)................................ I 2C-H (7517)................................ I 2C-I (7518)................................ I 2C-C (7519)................................ I 2C-N (7521)................................ I 2C-P (7524)................................ I 2C-T-4 (7532).............................. I AM-694 (7694).............................. I Metazocine (9240).......................... II ------------------------------------------------------------------------ The company plans to manufacture the listed controlled substances for distribution to their research and forensic customers conducting drug testing and analysis. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than March 26, 2013. Dated: January 14, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013-01556 Filed 1-24-13; 8:45 am] BILLING CODE 4410-09-P